公开(公告)号：US10716832B2

公开(公告)日：2020-07-21

申请号：US15488764

申请日：2017-04-17

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Maria Virginia Pascual

IPC: C07H21/04 ,  A61K38/20 ,  C07K16/24 ,  A61K38/17 ,  C07K14/545 ,  G01N33/68

Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

公开(公告)号：US10570398B2

公开(公告)日：2020-02-25

申请号：US15559362

申请日：2016-03-17

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay Goel ,  Kunitoshi Shigeyasu

IPC: A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/113 ,  C12Q1/6886 ,  G01N33/574 ,  A61P35/04 ,  A61P35/00 ,  C07K16/28 ,  C07K16/32

Abstract: Certain embodiments provide methods and compositions related to clinical management of cancer patients based on the expression level of TMCO3. Further embodiments involve methods and compositions related to treatment of cancer patients or patients determined to have an increased TMCO3 level relative to a control or a reference level that is normal or indicating favorable prognosis.

公开(公告)号：US20200009102A1

公开(公告)日：2020-01-09

申请号：US16517366

申请日：2019-07-19

Applicant: Baylor Research Institute

Inventor： Charles R. ROE

IPC: A61K31/225 ,  A23L33/10 ,  A23L33/12 ,  A23L33/175 ,  A23K20/174 ,  A23K20/158 ,  A23K50/10 ,  A23K50/75 ,  A23K50/80 ,  A61K31/202 ,  A61K31/19 ,  A61K31/22 ,  A23L2/52 ,  A61K9/00 ,  A61K38/47 ,  A23L33/115 ,  A23L33/16

Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

公开(公告)号：US20190231865A1

公开(公告)日：2019-08-01

申请号：US16372832

申请日：2019-04-02

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Dapeng LI

IPC: A61K39/145 ,  C12N7/00 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C07K16/28 ,  C07K14/195 ,  C12N5/0784 ,  A61K51/10 ,  A61K47/68 ,  C07K14/005

CPC classification number: A61K39/145 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/5154 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  C12N5/0639 ,  C12N7/00 ,  C12N2760/16122 ,  C12N2760/16134

Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

公开(公告)号：US10279030B2

公开(公告)日：2019-05-07

申请号：US15265236

申请日：2016-09-14

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon Oh ,  Dapeng Li

IPC: A61K39/00 ,  A61K39/395 ,  A01N63/00 ,  A61K39/145 ,  A61K51/10 ,  C07K16/28 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C12N5/0784 ,  C12N7/00 ,  A61K47/68

Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

公开(公告)号：US20190083442A1

公开(公告)日：2019-03-21

申请号：US15980262

申请日：2018-05-15

Applicant: Baylor Research Institute

Inventor： Charles R. ROE

IPC: A61K31/225 ,  A61K31/202 ,  A61K31/19 ,  A23L33/12 ,  A23L33/10 ,  A23L33/175 ,  A61K31/22 ,  A61K38/47 ,  A61K9/00 ,  A23L2/52 ,  A23K50/75 ,  A23K20/174 ,  A23K20/158 ,  A23K50/10 ,  A23K50/80 ,  A23L33/115 ,  A23L33/16 ,  A61K31/23 ,  A61K31/20

Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

公开(公告)号：US10111848B2

公开(公告)日：2018-10-30

申请号：US15257363

申请日：2016-09-06

Applicant: National Institute of Health and Medical Research ,  Baylor Research Institute

Inventor： Fanny Mochel ,  Raphael Schiffmann

IPC: A61K31/225 ,  A01N37/06 ,  A01N37/02 ,  A61K31/23 ,  A61K45/06 ,  A23L33/12 ,  A61B6/03 ,  A61B6/00 ,  A61K9/00 ,  A61K9/48 ,  G01N33/64

Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.

公开(公告)号：US20180298386A1

公开(公告)日：2018-10-18

申请号：US15559362

申请日：2016-03-17

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay GOEL ,  Kunitoshi SHIGEYASU

IPC: C12N15/113 ,  A61P35/00 ,  C07K16/28 ,  A61P35/04 ,  G01N33/574 ,  C07K16/32 ,  C12Q1/6886

CPC classification number: C12N15/1138 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/713 ,  A61P35/00 ,  A61P35/04 ,  C07K16/28 ,  C07K16/32 ,  C12N15/1135 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/531 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57419 ,  G01N2800/56

Abstract: Certain embodiments provide methods and compositions related to clinical management of cancer patients based on the expression level of TMCO3. Further embodiments involve methods and compositions related to treatment of cancer patients or patients determined to have an increased TMCO3 level relative to a control or a reference level that is normal or indicating favorable prognosis.

公开(公告)号：US10028902B2

公开(公告)日：2018-07-24

申请号：US15034929

申请日：2014-11-07

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Paul A. Grayburn ,  Shuyuan Chen

IPC: A61K9/00 ,  A61K38/26 ,  A61K45/06 ,  A61K9/127 ,  A61K38/22 ,  A61K31/616 ,  A61K31/7048 ,  A61K48/00 ,  C12N15/87

Abstract: Embodiments of the disclosure provide methods and/or compositions useful for an individual in need of treatment of a cardiac-related medical condition. In particular cases, GLP-1 is employed in a ultrasound targeted microbubble destruction (UTMD) system for delivery to cardiac tissue, thereby stimulating myocardial regeneration and, in at least some cases, reversal of cardiomyopathy.

公开(公告)号：US20180117067A1

公开(公告)日：2018-05-03

申请号：US15563304

申请日：2016-03-30

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Mazhar Adnan KANAK ,  Bashoo NAZIRUDDIN ,  Marlon F. Levy

IPC: A61K31/585 ,  A61P1/18

Abstract: It was discovered that NF-κB signaling pathway plays a central role in pancreatitis, and inhibition of NF-κB signaling has the potential to reduce the incidence of pancreatitis and protect pancreatic tissues from inflammatory damage. Aspects of the disclosure relate to a method for inhibiting or treating pancreatitis in a subject in need thereof comprising administering a therapeutically effective amount of an NF-κB signaling pathway inhibitor to the subject.